Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers Squibb Pravachol

Executive Summary

Supplemental NDAs for the use of pravastatin in the treatment of patients with Frederickson Type IV (S-026) and in the treatment of patients with Frederickson Type III (S-027) approved Jan. 18. The product also received approval for an optional starting dose of 40 mg/day (S-029) and for a change in time of dosing from administration at bedtime (S-030) to administration at any time of day with or without food
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS035468

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel